Distribution of Fluvoxamine and Identification of the Main Metabolite in a Fatal Intoxication.
Vignali C, Moretti M, Quaiotti J, Freni F, Tajana L, Osculati AMM, Morini L.
J Anal Toxicol · journal article; case reports · DOI 10.1093/jat/bkaa084 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för fluvoxamine. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
21 hitsFluvoxamine, melatonin and COVID-19.
Anderson GM.
Psychopharmacology (Berl) · letter; comment · DOI 10.1007/s00213-020-05753-zFluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM.
JAMA · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1001/jama.2020.22760Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials.
Zheng W, Xiang YQ, Cai DB, Yang XH, Zhang L, Zheng W, Lu XB, Tong YM, Huang X, Ungvari GS, Sim K, Ning YP, Xiang YT.
J Clin Psychopharmacol · meta-analysis; journal article · DOI 10.1097/jcp.0000000000001245Molecularly Imprinted Polymer Nanoparticles for Selective Solid Phase Extraction of Fluvoxamine in Human Urine and Plasma.
Soleimani M, Daryasari AP, Joshani P.
J Chromatogr Sci · journal article · DOI 10.1093/chromsci/bmz092The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study.
Hao Y, Hu Y, Wang H, Paudel D, Xu Y, Zhang B.
Nat Sci Sleep · research-article; journal article · DOI 10.2147/nss.s220947Characterization of microminipig as a laboratory animal for safety pharmacology study by analyzing fluvoxamine-induced cardiovascular and dermatological adverse reactions.
Tanikawa Y, Hagiwara-Nagasawa M, Kambayashi R, Goto A, Chiba K, Kitta K, Hoshiai K, Izumi-Nakaseko H, Naito AT, Sugiyama A.
Cardiovasc Toxicol · research support, non-u.s. gov't; journal article · DOI 10.1007/s12012-019-09509-wA Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine.
Albayrak Y, Beyazyüz M, Abbak Ö, Altındağ E.
Clin Psychopharmacol Neurosci · journal article; case reports; case-report · DOI 10.9758/cpn.2019.17.1.134Structural basis for recognition of diverse antidepressants by the human serotonin transporter.
Coleman JA, Gouaux E.
Nat Struct Mol Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41594-018-0026-8Structural basis for action by diverse antidepressants on biogenic amine transporters.
Wang H, Goehring A, Wang KH, Penmatsa A, Ressler R, Gouaux E.
Nature · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nature12648In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.
Mast N, Linger M, Clark M, Wiseman J, Stout CD, Pikuleva IA.
Mol Pharmacol · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1124/mol.112.080424Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases.
Furuse T, Hashimoto K.
Ann Gen Psychiatry · research-article; journal article · DOI 10.1186/1744-859x-9-28Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors.
Furuse T, Hashimoto K.
Ann Gen Psychiatry · research-article; journal article · DOI 10.1186/1744-859x-8-26Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene.
Nonogaki K, Ohba Y, Wakameda M, Tamari T.
Int J Neuropsychopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1017/s1461145708009619Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
Dell'Osso B, Allen A, Hollander E.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.6.15.2727Effects of fluvoxamine, a selective serotonin re-uptake inhibitor, on serotonin release from the mouse isolated ileum.
Minami M, Taguchi S, Kikuchi T, Endo T, Hamaue N, Hiroshige T, Liu Y, Yue W, Hirafuji M.
Res Commun Mol Pathol Pharmacol · research support, non-u.s. gov't; journal articleFluvoxamine: safety profile in extensive post-marketing surveillance.
Buchberger R, Wagner W.
Pharmacopsychiatry · journal article · DOI 10.1055/s-2002-31522Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
Cheer SM, Figgitt DP.
CNS Drugs · review; journal article · DOI 10.2165/00023210-200216020-00006Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo.
Larsen JT, Hansen LL, Spigset O, Brøsen K.
Eur J Clin Pharmacol · clinical trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s002280050643A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
Kiev A, Feiger A.
J Clin Psychiatry · comparative study; clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.4088/jcp.v58n0402Clinical pharmacokinetics of fluvoxamine.
Perucca E, Gatti G, Spina E.
Clin Pharmacokinet · review; journal article · DOI 10.2165/00003088-199427030-00002